Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2023 Jul;27(12):1–50. doi: 10.3310/GNBJ1387

A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma - the ASCOT study.

David G Charteris, Suzie Cro, Edward Casswell, Rhiannon Tudor Edwards, Victory Ezeofor, Bethany Anthony, Catey Bunce, Elizabeth Robertson, Joanna Kelly, Caroline Murphy, Philip Banerjee, Victoria R Cornelius
PMCID: PMC10591211  PMID: 37840322

Abstract

BACKGROUND

Eyes sustaining open globe trauma are at high risk of severe visual impairment. Proliferative vitreoretinopathy is the most common cause of retinal detachment and visual loss in eyes with open globe trauma. There is evidence from experimental studies and pilot clinical trials that the use of adjunctive steroid medication triamcinolone acetonide can reduce the incidence of proliferative vitreoretinopathy and improve outcomes of surgery for open globe trauma.

OBJECTIVE

The Adjunctive Steroid Combination in Ocular Trauma or ASCOT study aimed to investigate the clinical effectiveness of adjunctive triamcinolone acetonide given at the time of vitreoretinal surgery for open globe trauma.

DESIGN

A phase 3 multicentre double-masked randomised controlled trial randomising patients undergoing vitrectomy following open globe trauma to either adjunctive triamcinolone acetonide or standard care.

SETTING

Hospital vitreoretinal surgical services dealing with open globe trauma.

PARTICIPANTS

Patients undergoing vitrectomy surgery who had sustained open globe trauma.

INTERVENTIONS

Triamcinolone acetonide 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml sub-Tenon's or standard vitreoretinal surgery and postoperative care.

MAIN OUTCOME MEASURES

The primary outcome was the proportion of patients with at least 10 letters of improvement in corrected visual acuity at six months. Secondary outcomes included retinal detachment secondary to proliferative vitreoretinopathy, retinal reattachment, macula reattachment, tractional retinal detachment, number of operations, hypotony, elevated intraocular pressure and quality of life. Health-related quality of life was assessed using the EuroQol Five Domain and Visual Function Questionnaire 25 questionnaires.

RESULTS

A total of 280 patients were randomised; 129 were analysed from the control group and 130 from the treatment group. The treatment group appeared, by chance, to have more severe pathology on presentation. The primary outcome (improvement in visual acuity) and principal secondary outcome (change in visual acuity) did not demonstrate any treatment benefit for triamcinolone acetonide. The proportion of patients with improvement in visual acuity was 47% for triamcinolone acetonide and 43% for standard care (odds ratio 1.03, 95% confidence interval 0.61 to 1.75, p = 0.908); the baseline adjusted mean difference in the six-month change in visual acuity was -2.65 (95% confidence interval -9.22 to 3.92, p = 0.430) for triamcinolone acetonide relative to control. Similarly, the secondary outcome measures failed to show any treatment benefit. For two of the secondary outcome measures, stable complete retinal reattachment and stable macular retinal reattachment, outcomes for the treatment group were significantly worse for triamcinolone acetonide at the 5% level (respectively, odds ratio 0.59, 95% confidence interval 0.36 to 0.99, p = 0.044 and odds ratio 0.59, 95% confidence interval 0.35 to 0.98, p = 0.041) compared with control in favour of control. The cost of the intervention was £132 per patient. Health economics outcome measures (Early Treatment Diabetic Retinopathy Study, Visual Function Questionnaire 25 and EuroQol Five Dimensions) did not demonstrate any significant difference in quality-adjusted life-years.

CONCLUSIONS

The use of combined intraocular and sub-Tenon's capsule triamcinolone acetonide is not recommended as an adjunct to vitrectomy surgery for intraocular trauma. Secondary outcome measures are suggestive of a negative effect of the adjunct, although the treatment group appeared to have more severe pathology on presentation.

FUTURE WORK

The use of alternative adjunctive medications in cases undergoing surgery for open globe trauma should be investigated. Refinement of clinical grading and case selection will enable better trail design for future studies.

TRIAL REGISTRATION

This trial is registered as ISRCTN 30012492, EudraCT number 2014-002193-37, REC 14/LNO/1428, IRAS 156358, Local R&D registration CHAD 1031.

FUNDING

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (12/35/64) and will be published in full in Health Technology Assessment; Vol. 27, No. 12. See the NIHR Journals Library website for further project information.

Plain language summary

Despite advances in surgical techniques, eye trauma remains a leading cause of blindness and visual impairment. The main cause of trauma is a scarring process within the eye – proliferative vitreoretinopathy. There is good evidence from laboratory work and small-scale clinical studies that the addition of a steroid medication, triamcinolone acetonide, given in and around the eye at the time of surgery for eye trauma, can reduce the incidence of proliferative vitreoretinopathy scarring and improve the outcomes of surgery. The Adjunctive Steroid Combination in Ocular Trauma or ASCOT study was a multicentre clinical trial designed to test the use of triamcinolone acetonide as an addition to surgery to improve outcomes in eyes with ‘open globe’ penetrating injuries. A total of 280 patients were recruited and randomised to receive standard surgery or surgery with the additional steroid (triamcinolone acetonide). No benefit was found from the addition of the steroid medication. The addition of steroid medication was not good value for money. Secondary outcome measures suggested that triamcinolone acetonide may have had a negative effect on outcomes, although this may have been due to the presence of more severe cases amongst the patients allocated to receive the additional steroid (triamcinolone acetonide). The use of adjunctive triamcinolone acetonide in eye trauma cases undergoing surgery is therefore not recommended. Future studies with different additional medications and/or more targeted case selection are indicated to improve outcomes for eyes experiencing penetrating trauma.

Full text of this article can be found in Bookshelf.

References

  1. Esmaeli B, Elner SG, Schork MA, Elner VM. Visual outcome and ocular survival after penetrating trauma: a clinicopathologic study. Ophthalmology 1995;102(3):393–400. doi: 10.1016/s0161-6420(95)31009-3. [DOI] [PubMed]
  2. Negrel AD, Thylefors B. The global impact of eye injuries. Ophthalmic Epidemiol 1998;5(3):143–69. doi: 10.1076/opep.5.3.143.8364. [DOI] [PubMed]
  3. National Society to Prevent Blindness. Vision Problems in the US: Data Analysis. New York, NY: National Society to Prevent Blindness; 1980. pp. 25–26.
  4. Schein OD, Hibberd PL, Shingleton BJ, Kunzweiler T, Frambach DA, Seddon JM, et al. The spectrum and burden of ocular injury. Ophthalmology 1988;95(3):300–5. doi: 10.1016/s0161-6420(88)33183-0. [DOI] [PubMed]
  5. Desai P, MacEwen CJ, Baines P, Minassian DC. Incidence of cases of ocular trauma admitted to hospital and incidence of blinding outcome. Br J Ophthalmol 1996;80(7):592–6. doi: 10.1136/bjo.80.7.592. [DOI] [PMC free article] [PubMed]
  6. Pinna A, Atzeni G, Patteri P, Salvo M, Zanetti F, Carta F. Epidemiology, visual outcome, and hospitalization costs of open globe injury in northern Sardinia, Italy. Ophthalmic Epidemiol 2007;14(5):299–305. doi: 10.1080/09286580701198753. [DOI] [PubMed]
  7. Cillino S, Casuccio A, Di Pace F, Pillitteri F, Cillino G. A five-year retrospective study of the epidemiological characteristics and visual outcomes of patients hospitalized for ocular trauma in a Mediterranean area. BMC Ophthalmol 2008;8:6. doi: 10.1186/1471-2415-8-6. [DOI] [PMC free article] [PubMed]
  8. Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, et al. Post-traumatic proliferative vitreoretinopathy: the epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997;104(7):1166–73. doi: 10.1016/s0161-6420(97)30167-5. [DOI] [PubMed]
  9. Spiegel D, Nasemann J, Nawrocki J, Gabel VP. Severe ocular trauma managed with primary pars plana vitrectomy and silicone oil. Retina 1997;17(4):275–85. doi: 10.1097/00006982-199707000-00001. [DOI] [PubMed]
  10. Framme C, Roider J. [Epidemiology of open globe injuries]. (In German.) Klin Monbl Augenheilkd 1999;215(5):287–93. doi: 10.1055/s-2008-1034716. [DOI] [PubMed]
  11. Mittra RA, Mieler WF. Controversies in the management of open-globe injuries involving the posterior segment. Surv Ophthalmol 1999;44(3):215–25. doi: 10.1016/s0039-6257(99)00104-6. [DOI] [PubMed]
  12. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 2002;16(4):369–74. doi: 10.1038/sj.eye.6700194. [DOI] [PubMed]
  13. Patel NN, Bunce C, Asaria RH, Charteris DG. Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina 2004;24(6):883–7. doi: 10.1097/00006982-200412000-00007. [DOI] [PubMed]
  14. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995;79(10):953–60. doi: 10.1136/bjo.79.10.953. [DOI] [PMC free article] [PubMed]
  15. Johnson RN, Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology 1988;95(3):312–7. doi: 10.1016/s0161-6420(88)33181-7. [DOI] [PubMed]
  16. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90(6):810–6. doi: 10.1016/s0002-9394(14)75196-7. [DOI] [PubMed]
  17. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina 1997;17(1):44–50. doi: 10.1097/00006982-199701000-00009. [DOI] [PubMed]
  18. Albini TA, Abd-El-Barr MM, Carvounis PE, Iyer MN, Lakhanpal RR, Pennesi ME, et al. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48(1):390–5. doi: 10.1167/iovs.06-0145. [DOI] [PubMed]
  19. Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis--a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 1982;219(6):268–71. doi: 10.1007/BF00231411. [DOI] [PubMed]
  20. Williams RG, Chang S, Comaratta MR, Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 1996;234(8):496–503. doi: 10.1007/BF00184858. [DOI] [PubMed]
  21. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 2005;40(5):598–604. doi: 10.1016/S0008-4182(05)80052-3. [DOI] [PubMed]
  22. Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007;38(5):365–70. doi: 10.3928/15428877-20070901-02. [DOI] [PubMed]
  23. Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 2008;115(11):1938–43. doi: 10.1016/j.ophtha.2008.05.016. [DOI] [PubMed]
  24. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al.; Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245–51. doi: 10.1001/archophthalmol.2008.610. [DOI] [PMC free article] [PubMed]
  25. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127(9):1115–28. doi: 10.1001/archophthalmol.2009.233. [DOI] [PMC free article] [PubMed]
  26. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29(1):27–33. doi: 10.1016/s0886-3350(02)01441-4. [DOI] [PubMed]
  27. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26(4):277–81. doi: 10.1111/j.1442-9071.1998.tb01330.x. [DOI] [PubMed]
  28. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20(5):554–5. doi: 10.1097/00006982-200005000-00024. [DOI] [PubMed]
  29. Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240(6):423–9. doi: 10.1007/s00417-002-0454-2. [DOI] [PubMed]
  30. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina 2008;28(4):573–80. doi: 10.1097/IAE.0b013e31816079e8. [DOI] [PubMed]
  31. Banerjee PJ, Xing W, Bunce C, Woodcock M, Chandra A, Scott RA, Charteris DG. , Charteris DG Triamcinolone during pars plana vitrectomy for open globe trauma: a pilot randomised controlled clinical trial. Br J Ophthalmol 2016;100(7):949–55. doi: 10.1136/bjophthalmol-2015-307347. [DOI] [PubMed]
  32. Banerjee PJ, Cornelius VR, Phillips R, Lo JW, Bunce C, Kelly J, et al. Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial. Trials 2016;17(1):339. doi: 10.1186/s13063-016-1445-7 doi: 10.1186/s13063-016-1445-7. [DOI] [PMC free article] [PubMed]
  33. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332–c332. doi: 10.1136/bmj.c332. [DOI] [PMC free article] [PubMed]
  34. EuroQol Research Foundation. EQ-5D-5L User Guide. 2019. URL: http://www.euroqol.org/about-eq-5d/publications/user-guide.html (accessed 19 May 2022).
  35. van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15(5):708–15. doi: 10.1016/j.jval.2012.02.008. [DOI] [PubMed]
  36. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119(7):1050–8. doi: 10.1001/archopht.119.7.1050. [DOI] [PubMed]
  37. Curtis L, Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit at the University of Kent; 2014. URL: http://www.pssru.ac.uk/project-pages/unit-costs/2014 (accessed 9 July 2016).
  38. NHS Business Services Authority. Prescription Cost Analysis – England 2019. URL: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-cost-analysis-england-2019 (accessed 10 May 2023).
  39. Department of Health. NHS reference costs 2013 to 2014. 2015. URL: https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 (accessed 9 July 2016).
  40. Carpenter J, Kenward MG. Missing data in randomised controlled trials: a practical guide. Birmingham: National Institute for Health Research; 2008. URL: https://researchonline.lshtm.ac.uk/id/eprint/4018500 (accessed 10 May 2023).
  41. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004;13(5):405–15. doi: 10.1002/hec.903. [DOI] [PubMed]
  42. Assi A, Khoueir Z, Helou C, Fakhoury H, Cherfan G. Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries. Eye 2019;33:1261–70. doi: 10.1038/s41433-019-0408-0. [DOI] [PMC free article] [PubMed]
  43. Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N, Charteris DG. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology 2017;124:757–67. doi: 10.1016/j.ophtha.2017.01.021. [DOI] [PubMed]
  44. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 1998;126(4):550–9. doi: 10.1016/s0002-9394(98)00115-9. [DOI] [PubMed]
  45. Charteris DG. Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment. Eye 2020;34:241–5. doi: 10.1038/s41433-019-0699-1. [DOI] [PMC free article] [PubMed]
  46. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RHY, Bunce C; PVR Study Group. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004;111(12):2240–5. doi: 10.1016/j.ophtha.2004.05.036. [DOI] [PubMed]
  47. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007;114(4):698–704. doi: 10.1016/j.ophtha.2006.08.042. [DOI] [PubMed]
  48. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001;108(7):1179–83. doi: 10.1016/s0161-6420(01)00589-9. [DOI] [PubMed]
  49. Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, Charteris DG. Glial remodelling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2005;46:329–42. doi: 10.1167/iovs.03-0518. [DOI] [PubMed]
  50. Charteris DG, Downie J, Aylward GW, Sethi C, Luthert P. Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 2007;245:93–100. doi: 10.1007/s00417-006-0323-5. [DOI] [PubMed]
  51. Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 2016;51:125–55. doi: 10.1016/j.preteyeres.2015.07.005. [DOI] [PubMed]

RESOURCES